- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05042141
Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR) (KOVIR)
A Study to Evaluate the Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients Without Symptoms of Acute Respiratory Distress
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus. The reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell.
The hard capsule KOVIR is a product based on the traditional medicine named "Nhân sâm bài độc táng" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus. The reported symptoms have included, but are not limited to fever or chills, cough, shortness of breath, muscle aches, headaches, loss of taste or smell, diarrhea, dizziness, sore throat, abdominal pain, anorexia, and vomiting.
The hard capsule KOVIR is a product based on the traditional prescription named "Nhân sâm bài độc táng" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.
The study timeline is expected about 7 months, including enrolment period, 14 days of treatment, data entry and analysis.
The study compares between standard dose regimen of KOVIR combined with background treatment in COVID-19 patients and placebo combined with background treatment in COVID-19 patients.
All participants will be treated and followed up in 14-day period. In case the participant meets the discharge criteria before 14 days, discontinuing the study drug will be done at the discretion of the investigators.
Screening procedures occur at Day 1. Periodic assessments are conducted daily from Day 2-14. Finally, End of study visit is conducted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ho Chi Minh City, Vietnam, 700000
- Traditional Medicine Institute in Ho Chi Minh City
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age from 18 to 65 years old, Vietnamese nationality
- Participants diagnosed with Positive result of SARS-CoV-2 using real time RT-PCR test, Ct value <30 (equivalent to viral load > 3log)
- Voluntary participation in the study by signing an informed consent
- Ability to adhere to treatment according to the investigator's assessment
Exclusion Criteria:
- Symptoms of severe upper and lower respiratory tract infections such as dyspnea, SpO2<93%.
Acute reduction of ventilation function of respiratory apparatus and/or respiration function of the lung in any of the following three groups:
- Respiratory distress due to hypoxemia with PaO2 less than 60mmHg when breathing room air.
- Respiratory distress due to hypercapnia with PaCO2 above 50mmHg
- Mixed respiratory distress accompanied by both a decrease in PaO2 and an increase in PaCO2
- Allergy/intolerance to any component of the study drug.
- Inability to administer medicine.
- Severe pneumonia as assessed by the investigator.
- Inability to comply with study procedures or to ensure compliance with study drug administration as assessed by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KOVIR
Standard dose, 3 capsules/time x 3 times/day x 14 days
|
KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
|
Placebo Comparator: Placebo
Placebo, 3 capsules/time x 3 times/day x 14 days
|
Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in viral load of SARS-CoV-2
Time Frame: up to 14 days
|
Daily assessment using qRT-PCR test
|
up to 14 days
|
The time from baseline to the peak of viral load of SARS-CoV-2
Time Frame: up to 14 days
|
Daily assessment using qRT-PCR test
|
up to 14 days
|
The time from baseline to no SARS-CoV-2 virus detection
Time Frame: up to 14 days
|
Daily assessment using qRT-PCR test
|
up to 14 days
|
Number of participants without SARS-CoV-2 virus detection after 7 days of treatment
Time Frame: after 7 days of treatment
|
Assessment using qRT-PCR test
|
after 7 days of treatment
|
Number of participants without SARS-CoV-2 virus detection after 14 days of treatment
Time Frame: after 14 days of treatment
|
Assessment using qRT-PCR test
|
after 14 days of treatment
|
Number of participants with respiratory distress complications requiring treatment
Time Frame: up to 14 days
|
Appearance of symptoms of respiratory distress complications requiring treatment
|
up to 14 days
|
Change in the severity of daily symptoms
Time Frame: up to 14 days
|
Scale: 0 = Asymptomatic, 1 = Mild, 2 = Moderate, 3 = Severe
|
up to 14 days
|
The cell counts of TD4 and TD8 change from 7 days to 14 days of treatment
Time Frame: at day 7 and 14 days of treatment
|
Laboratory test of TD4 and TD8
|
at day 7 and 14 days of treatment
|
Number of Participants with Adverse Events as Assessed by CTCAE v5.0
Time Frame: up to 30 days after last dose
|
Study drug-related adverse events, adverse events leading to study termination, serious adverse events (SAE)
|
up to 30 days after last dose
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Loc Huynh, SL II., MD., Traditional Medicine Institute in Ho Chi Minh City
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YDHDT-KOVIR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on KOVIR oral capsule
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyNot yet recruiting
-
Sao Thai Duong Joint Stock CompanyVietstar Biomedical ResearchRecruiting
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated
-
Georgetown UniversityNational Institutes of Health (NIH)RecruitingDementia With Lewy BodiesUnited States